Study estimates the lifetime benefit of combination therapy in patients with kidney disease without diabetes
Green beans can be one of the healthiest dishes at the holiday table
22 November 2022Screening all older adults aged 40-70 years would find undiagnosed type 2 diabetes cases at least two years earlier
22 November 2022Study estimates the lifetime benefit of combination therapy in patients with kidney disease without diabetes
New research in Clinical Journal of the American Society of Nephrology highlights the potential to lower the burden of chronic kidney disease (CKD) complications by delaying or even preventing kidney failure and premature death if currently available treatments are appropriately utilized—specifically, offering patients combination therapy of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers (ACE inhibitors/ARBs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
